Success Story: From Neurological Treatment Research to NIW Approval
On April 24th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Researcher in the Field of Clinical Medicine (Approval Notice).
General Field: Clinical Medicine
Position at the Time of Case Filing: Researcher
Country of Origin: Egypt
Country of Residence at the Time of Filing: Egypt
Approval Notice Date: April 24th, 2026
Processing Time: 6 months, 14 days (Premium Processing Requested)
Case Summary:
For patients with serious neurological conditions, the difference between recovery and lasting harm often comes down to timing, treatment selection, and the quality of the evidence guiding those choices. This NIW case centered on research designed to improve exactly that. The petition was initially filed under regular processing, with a Premium Processing request later submitted on March 4th, 2026. His work focused on improving diagnosis, surgical decision-making, and treatment outcomes in high-burden neurological and medical conditions.
His proposed endeavor involved conducting research and evidence-based analyses to improve care in areas such as neurocritical care, stroke, spinal cord injury, and neurodegenerative disease. North America Immigration Law Group (Chen Immigration Law Associates) showed that this work had national importance because these conditions remain highly prevalent, medically complex, and costly, while many existing interventions still suffer from limited translational success or inconsistent real-world outcomes. The petition argued that better evidence in these areas directly supports better patient care in the United States.
Our legal team documented 47 peer-reviewed journal articles, 2 accepted journal articles, 44 conference abstracts, 175 citations, and 6 completed peer reviews. Multiple publications ranked among the most-cited Clinical Medicine papers for their publication years, including one in the top 1% and several in the top 10%. Other researchers had also relied on his studies in later work on neurosurgical practice, spinal cord injury treatment, and AI-assisted neurological diagnosis, showing that his findings were already helping shape the field.
We were proud to help secure this NIW approval for a clinical medicine researcher whose work supports more accurate diagnosis, better treatment selection, and stronger evidence for neurological care. This case shows the value of presenting medical research not as abstract publication output, but as work that can directly improve clinical decisions and patient outcomes in the United States.